Stem Cell & Organoid Facility
Stem cell research provides an exciting model and tool for numerous areas of research. The facility offers a range of custom iPSC services including organoid model systems of disease which will increase the scope of stem cell research at CMRI and affiliated Institutions.
Our goal is to create a broadly available resource of human iPS cells-derived products and derivative tissues to accelerate research.
Pluripotent stem cells, including embryonic and induced pluripotent stem (iPS) cells, are undifferentiated cells that can differentiate into any cell type in the human body. They can survive and replicate indefinitely in the dish providing an unlimited source of cells for regenerative medicine, modelling diseases and development of new therapeutic approaches. For example, large numbers of drugs can be tested to find suitable treatments; this is called drug screening.
The generation of iPS cells is referred to as reprogramming and involves the expression of four pluripotency genes in adult cells, such as skin and blood cells. We utilise efficient episomal reprogramming methods to deliver these pluripotency genes. The Facility offers reprogramming, expansion and banking of iPS cell lines. These cell lines can also be maintained by our experienced scientific team to generate terminally differentiated cells of your choice.
Maintenance of iPS cell lines
Access to a number of fully characterised cell lines is sometimes impossible within the constraints of individual laboratories due to the laborious processes needed to maintain these cells. The Facility offers the maintenance of reprogrammed iPS cell lines under optimal culture conditions in order to maintain their pluripotency and avoid spontaneous differentiation. The maintenance of the iPS cell lines in our laboratory facilitates their use in our established differentiation protocols.
Differentiation of iPS cell lines
Our scientific team is specialised in the differentiation of iPS cell lines into a number of tissues.
Tissue-specific cell types
iPS cell cultures can be differentiated into specific cell types. A number of robust differentiation protocols have been developed to generate highly purified cultures of progenitors as well as mature cell types from iPS cell lines.
The Facility offers the differentiation of iPS cell lines into human neurons, cardiomyocytes, and hepatocytes. Please, contact us if you are interested in other cell types.
Organoids are mini-organs grown in the dish using 3D differentiation systems. These offer ideal models to investigate biology of tissues and organs. Organoids can be derived not only from pluripotent stem cells but also from adult stem/progenitor cells. We provide a range of organoids that can be derived from control and diseased iPS cells.
Please contact us to enquire if we can generate organoids from your system of interest.
CMRI has a number of core facilities that complement the services provided by the Stem Cell & Organoid Facility. We aim to provide a comprehensive range of services to facilitate all aspects of customers' research.
Cellbank Australia provides high-quality controlled cell lines including iPS cell lines. We will use CellBank to test, secure storage, and transport of your iPS cell lines.
CellBank website: http://www.cellbankaustralia.com
Email: [email protected]
Phone: +61 2 8865 2850
Fax: +61 2 9687 2120
Genome editing of iPS cell lines
The CRISPR-Cas9 system is able to achieve highly specific and precise targeting for the genetic manipulation of cell lines. Gene-editing of iPS cells allows researchers to create isogenic cell models correcting or introducing key disease mutations. We work together with VGEF to generate or correct your particular disease iPS cell line. Contact Email: [email protected]
Interested in performing a comprehensive analysis of your model disease organoid? We work together with CMRI’s Single Cell Genomics and Biomedical Proteomics core facilities to offer single cell transcriptome and proteomics of the organoids generated by Stem Cell & Organoid Facility.
Email: [email protected]